Literature DB >> 1666360

Cross-resistance and cross-susceptibility between fluoroquinolone agents.

A L Barry1, P C Fuchs.   

Abstract

The results of broth microdilution susceptibility tests with 750 bacterial isolates were used to directly compare six different fluoroquinolone antibiotics (ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, ofloxacin and temafloxacin). Against enteric bacilli, enoxacin and lomefloxacin were similar in their spectra of activity but they differed from the other drugs tested. Against the non-enteric gram-negative bacilli, ciprofloxacin differed from enoxacin and lomefloxacin: fleroxacin, ofloxacin and temafloxacin were nearly identical in their activity. For routine susceptibility tests, ofloxacin and fleroxacin were similar in activity and either drug could be used as a class representative for predicting susceptibility to the other fluoroquinolone agents. Occasionally, strains that are resistant to the class representative may be susceptible to other members of the fluoroquinolone class, but those that are susceptible to the class representative are rarely resistant to the other compounds.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666360     DOI: 10.1007/bf01984922

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

2.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

3.  Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.

Authors:  G J Duckworth; J D Williams
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

4.  Aerobic and anaerobic susceptibility tests with three tetracyclines. Reassessment of the "class concept" of disk testing.

Authors:  A L Barry; D L Draper; M K Wong
Journal:  Am J Clin Pathol       Date:  1978-11       Impact factor: 2.493

5.  In vitro activity of mezlocillin and azlocillin compared with that of four other penicillins and two aminoglycosides.

Authors:  A L Barry; C Thornsberry; R N Jones; T L Gavan
Journal:  Cleve Clin Q       Date:  1980

6.  A critical evaluation of nalidixic acid in urinary-tract infections.

Authors:  A R Ronald; M Turck; R G Petersdorf
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

7.  The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo.

Authors:  P B Fernandes; C W Hanson; J M Stamm; C Vojtko; N L Shipkowitz; E St Martin
Journal:  J Antimicrob Chemother       Date:  1987-04       Impact factor: 5.790

8.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  In-vitro selection of bacteria resistant to the 4-quinolone agents.

Authors:  D I Limb; D J Dabbs; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

10.  Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).

Authors:  G Verschraegen; G Claeys; A M Van den Abeele
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

View more
  7 in total

1.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.

Authors:  B N Hota; S Pur; L Phillips; R A Weinstein; J Segreti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

3.  In vitro activity of Bay y 3118, a new quinolone.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 4.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  The epidemiology of bacterial resistance to quinolones.

Authors:  J F Acar; T F O'Brien; F W Goldstein; R N Jones
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

7.  Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound.

Authors:  Nikki Y T Man; Daniel R Knight; Scott G Stewart; Allan J McKinley; Thomas V Riley; Katherine A Hammer
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.